Sanofi Acquires Tidal Therapeutics

Must Read

- Advertisement -

…adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

April 9, 2021 – Sanofi today acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells.

The new technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones.

Sanofi delivers strong 2019 business EPS growth of 6.8% at CER Brandspurng

“We anticipate that this next generation, the off-the-shelf approach has the potential to bring CAR-T cell therapy to a much broader patient population,” said Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi. “We believe that the underlying mRNA targeting platform will create disruptive therapeutic approaches across a variety of oncology and autoimmune conditions.”

Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram immune cells inside the body.

- Advertisement -

The technology delivers mRNA cargos selectively to designated types of cells in the body, with initial applications targeting specific types of immune cells.

Read Also:  9mobile Launches Vehicle Tracking Solution

The in vivo approach is designed to provide similar efficacy to current ex vivo (outside the body) approaches where immune cells are genetically modified to enhance their therapeutic properties (such as chimeric antigen receptor [CAR]-expressing T-cells), with the potential for improved safety, outpatient dosing, and repeat dosing. Currently, Tidal Therapeutics has ongoing preclinical programs including in vivo reprogramming of T cells or other types of immune cells for cancer indications.

“Teaming up with Sanofi gives us the opportunity to further develop our unique platform and rapidly apply it to ultimately help patients across a range of diseases,” said Ulrik Nielsen, President and CEO, Tidal Therapeutics.

- Advertisement -
spot_imgspot_img

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Latest News

Visa Currencycloud

Visa to Acquire London fintech Currencycloud for £700M

07/22/2021 - Visa today announced it has signed a definitive agreement to acquire Currencycloud, a global platform that enables banks and fintech to provide...
- Advertisement -
spot_imgspot_img

Latest News

Visa to Acquire London fintech Currencycloud for £700M

07/22/2021 - Visa today announced it has signed a definitive agreement to acquire Currencycloud, a global platform that enables...
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -spot_imgspot_img